Rating versus ranking in a Delphi survey: a randomized controlled trial
Del Grande C., Kaczorowski J., Trials, 2023
Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17
Larney S., Jones N.R., Hickman M., Nielsen S., Ali R., Degenhardt L., Addiction, 2023
Personality-specific pathways from bullying victimization to adolescent alcohol use: a multilevel longitudinal moderated mediation analysis
Laroque F.M., Boers E., Afzali M.H., Conrod P.J., Development and Psychopathology, 2023
Personality-specific pathways from bullying victimization to adolescent alcohol use: a multilevel longitudinal moderated mediation analysis
Laroque FM, Boers E, Afzali MH, Conrod PJ., Development and Psychopathology, 2023
Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis
Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, Bonn M, Touesnard N, Henderson N, Bowles J, Boyd J, Brunelle C, Eeuwes J, Fikowski J, Gomes T, Guta A, Hyshka E, Ivsins A, Kennedy MC, Laurence G, Martignetti L, Nafeh F, Salters K, Tu D, Strike C, Pauly B, Werb D. Int J Drug Policy. 2023
Use of Cannabis as a Harm Reduction Strategy Among People Who Use Drugs: A Cohort Study
Mok J, Milloy MJ, Grant C, Lake S, DeBeck K, Hayashi K, Kerr T, Socías ME., Cannabis Cannabinoid Res. 2023
Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada
Cui Z, Hayashi K, Bach P, Milloy MJ, Kerr T., J Subst Use Addict Treat. 2023
Unleashing compassionate care: canine-assisted intervention as a promising harm reduction approach to prisonization in Canada and its relevance to forensic psychiatry
Gibson M, Dell CA, Chalmers D, Rath G, Mela M. , Front Psychiatry., 2023
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
Bastien G, McAnulty C, Ledjiar O, Socias ME, Le Foll B, Lim R, Hassan AN, Brissette S, Marsan S, Talbot A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Can J Psychiatry. 2023
Preclinical evidence for the use of the atypical antipsychotic, brexpiprazole, for opioid use disorder
Nickols JER, Dursun SM, Taylor AMW., Neuropharmacology. 2023
